Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Harvey

Showing results (401-410 of 419) with videos related to

Pageof 42
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trialRuben A Mesa, Jason Gotlib, Vikas Gupta, et al.
Metrologia|February 23, 2016
Metrological challenges for measurements of key climatological observables: Oceanic salinity and pH, and atmospheric humidity. Part 1: OverviewR Feistel, R Wielgosz, S A Bell, et al.
Expert Opinion on Drug Discovery|February 23, 2019
Animal models of major depressive disorder and the implications for drug discovery and developmentKonstantin A Demin, Maxim Sysoev, Maria V Chernysh, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|October 18, 2018
Efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trialMelanie M Ashton, Michael Berk, Chee H Ng, et al.
Journal of Hematology & Oncology|February 24, 2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Haematologica|January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
British Journal of Haematology|March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
The New England Journal of Medicine|March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 10, 2025
The efficacy of adjunctive <i>Garcinia mangostana</i> Linn. (mangosteen) pericarp extract for bipolar depression: 24-week randomised controlled trialOlivia M Dean, Susan M Cotton, Melanie M Ashton, et al.
Haematologica|September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Pageof 42

Showing results (401-410 of 419) with videos related to

Sort By:
Pageof 42
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trialRuben A Mesa, Jason Gotlib, Vikas Gupta, et al.
Metrologia|February 23, 2016
Metrological challenges for measurements of key climatological observables: Oceanic salinity and pH, and atmospheric humidity. Part 1: OverviewR Feistel, R Wielgosz, S A Bell, et al.
Expert Opinion on Drug Discovery|February 23, 2019
Animal models of major depressive disorder and the implications for drug discovery and developmentKonstantin A Demin, Maxim Sysoev, Maria V Chernysh, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|October 18, 2018
Efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trialMelanie M Ashton, Michael Berk, Chee H Ng, et al.
Journal of Hematology & Oncology|February 24, 2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Haematologica|January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
British Journal of Haematology|March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
The New England Journal of Medicine|March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 10, 2025
The efficacy of adjunctive <i>Garcinia mangostana</i> Linn. (mangosteen) pericarp extract for bipolar depression: 24-week randomised controlled trialOlivia M Dean, Susan M Cotton, Melanie M Ashton, et al.
Haematologica|September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Pageof 42